Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha...

Area of Science:

• Nephrology
• Endocrinology
• Mineral Metabolism

Background:

• Secondary hyperparathyroidism is a common complication in chronic hemodialysis patients.
• Effective management is crucial to prevent bone disease and cardiovascular complications.
• Current treatment strategies aim to control parathyroid hormone (PTH) levels and mineral imbalances.

Purpose of the Study:

• To evaluate the efficacy of oral alfacalcidol and calcium carbonate in managing secondary hyperparathyroidism in hemodialysis patients.
• To assess changes in calcium set point as an indicator of treatment effectiveness.
• To investigate the impact of the treatment regimen on bone mineral content and other biochemical markers.

Main Methods:

• 12 chronic hemodialysis patients were studied over 12 months.
• Treatment included calcium carbonate as a phosphate binder and oral alfacalcidol (0.25-1.0 µg/day).
• Dialysate calcium concentration was maintained at 1.65 mmol/l.
• Measurements included ionized calcium, intact PTH, total calcium, phosphate, alkaline phosphatase, aluminum, and calcium set point.

Main Results:

• No significant changes were observed in ionized calcium, intact PTH, total calcium, phosphate, alkaline phosphatase, or aluminum levels.
• The relative calcium set point significantly worsened, indicating a rightward shift.
• 25% of patients developed hypercalcemia (total calcium > 2.65 mmol/l), and bone mineral content decreased.

Conclusions:

• The studied dose of oral alfacalcidol, calcium carbonate, and dialysate calcium concentration were insufficient to halt secondary hyperparathyroidism progression.
• Calcium set point measurement may serve as an early indicator of treatment failure in managing hyperparathyroidism.
• The treatment regimen led to demineralization and a risk of hypercalcemia in hemodialysis patients.